c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Constitutive c-Abl activity (CST-Abl) was previously shown to reduce triple-negative breast cancer (TNBC) tumorigenicity.
• This effect was linked to downregulated matrix metalloproteinase (MMP) and upregulated p21Waf1/Cip1 expression.

Purpose of the Study:

• To investigate the association between c-Abl expression and breast cancer patient survival.
• To elucidate the mechanisms by which CST-Abl suppresses mammary tumorigenesis and metastatic progression.

Main Methods:

• Analysis of c-Abl expression in breast cancer patient samples and correlation with survival data.
• In vivo studies using 4T1 cell models in mice to assess tumorigenicity and cancer stem cell exhaustion.
• Genetic manipulation of MMP-9 and p21 expression in CST-Abl-expressing cells.
• Investigation of TGF-β1 and p53 signaling pathways.

Main Results:

• Decreased c-Abl expression is significantly associated with reduced relapse-free survival in breast cancer patients, especially those with invasive and basal phenotypes.
• CST-Abl expression in 4T1 cells led to innocuous persistence in mouse mammary glands by exhausting cancer stem cells.
• Restoring MMP-9 did not rescue malignancy, but p21 deficiency partially restored tumorigenicity.
• CST-Abl expression induced TGF-β1 production, reactivating p53 and leading to p21 upregulation and TNBC senescence via Smad signaling.

Conclusions:

• A novel c-Abl:p53:p21 signaling axis acts as a potent suppressor of mammary tumorigenesis and metastasis.
• Targeting this axis may offer therapeutic strategies for TNBC and other aggressive breast cancers.